Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 142,600 shares, a decrease of 56.7% from the December 15th total of 329,400 shares. Currently, 3.7% of the company’s stock are short sold. Based on an average daily trading volume, of 136,200 shares, the short-interest ratio is currently 1.0 days.
Institutional Investors Weigh In On Cara Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new stake in shares of Cara Therapeutics in the 3rd quarter worth about $29,000. FMR LLC increased its stake in shares of Cara Therapeutics by 18.5% in the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 32,789 shares during the period. Finally, Disciplined Growth Investors Inc. MN increased its stake in shares of Cara Therapeutics by 6.6% in the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 120,660 shares during the period. 44.66% of the stock is currently owned by institutional investors.
Cara Therapeutics Stock Performance
CARA remained flat at $4.66 on Tuesday. 42,996 shares of the company traded hands, compared to its average volume of 96,441. The company’s fifty day simple moving average is $4.11 and its two-hundred day simple moving average is $3.86. Cara Therapeutics has a 52-week low of $2.71 and a 52-week high of $13.80. The firm has a market capitalization of $21.29 million, a price-to-earnings ratio of -2.66 and a beta of 0.51.
Analyst Upgrades and Downgrades
View Our Latest Report on Cara Therapeutics
About Cara Therapeutics
Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Read More
- Five stocks we like better than Cara Therapeutics
- How to Invest in the FAANG Stocks
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Why Invest in 5G? How to Invest in 5G Stocks
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.